InflaRx N.V. (IFRX)
NASDAQ: IFRX
· Real-Time Price · USD
1.58
0.20 (14.49%)
At close: Oct 03, 2025, 3:59 PM
1.62
2.53%
After-hours: Oct 03, 2025, 07:48 PM EDT
14.49% (1D)
| Bid | 1.43 |
| Market Cap | 107.04M |
| Revenue (ttm) | 162.83K |
| Net Income (ttm) | -45.29M |
| EPS (ttm) | -0.87 |
| PE Ratio (ttm) | -1.82 |
| Forward PE | -2.06 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.63 |
| Volume | 601,607 |
| Avg. Volume (20D) | 552,084 |
| Open | 1.39 |
| Previous Close | 1.38 |
| Day's Range | 1.39 - 1.62 |
| 52-Week Range | 0.71 - 2.81 |
| Beta | 1.41 |
| Ex-Dividend Date | n/a |
About IFRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IFRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IFRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsInflaRx N.V. is scheduled to release its earnings on
Nov 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-2.96%
InflaRx shares are trading lower after the company...
Unlock content with
Pro Subscription
4 months ago
-59.86%
InflaRx N.V. shares are trading lower after the company announced hat the Independent Data Monitoring Committee conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility.
